Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Large-scale testing (Phase 3)Active Not RecruitingNCT03091660
What this trial is testing

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Who this might be right for
Stage 0 Bladder Urothelial CarcinomaStage 0is Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma
SWOG Cancer Research Network 1,000
Large-scale testing (Phase 3)Study completedNCT00406068
What this trial is testing

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Neoplasms
Bioniche Life Sciences Inc. 129
Early research (Phase 1)Active Not RecruitingNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 6
Early research (Phase 1)Active Not RecruitingNCT05768347
What this trial is testing

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

Who this might be right for
Urothelial CarcinomaNon-Invasive Bladder Urothelial Carcinoma
H. Lee Moffitt Cancer Center and Research Institute 9
Not applicableLooking for participantsNCT05123625
What this trial is testing

Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC

Who this might be right for
Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University 200
Not applicableNot Yet RecruitingNCT07053748
What this trial is testing

Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy

Who this might be right for
High - Risk NMIBC
Peking University First Hospital 30
Not applicableEnded earlyNCT04412070
What this trial is testing

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients

Who this might be right for
Bladder Cancer
Hopital Foch 20
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)Looking for participantsNCT06770582
What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Who this might be right for
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8
National Cancer Institute (NCI) 160
Large-scale testing (Phase 3)Looking for participantsNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)Looking for participantsNCT04752722
What this trial is testing

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Who this might be right for
Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-muscle Invasive Bladder Cancer
enGene, Inc. 350
Large-scale testing (Phase 3)Active Not RecruitingNCT06462001
What this trial is testing

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Who this might be right for
Transitional Cell CarcinomaTransurethral Resection
Nottingham University Hospitals NHS Trust 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07064863
What this trial is testing

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

Who this might be right for
NMIBCNon-Muscle Invasive Bladder Urothelial CarcinomaBladder (Urothelial, Transitional Cell) Cancer+1 more
Queen's University 31
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Not applicableEnded earlyNCT02202044
What this trial is testing

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Who this might be right for
Bladder Carcinoma
University of Colorado, Denver 13
Testing effectiveness (Phase 2)UnknownNCT04730232
What this trial is testing

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
High-RiskNon-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07356791
What this trial is testing

Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06971614
What this trial is testing

T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Who this might be right for
Nonmuscle-invasive Bladder Cancer
ImmVira Pharma Co. Ltd 160
Next Page